Placebo News and Research

RSS

Dextrose gel could treat neonatal hypoglycemia

A cheap and easy-to-administer dextrose gel should be used to treat low blood sugars in newborns (neonatal hypoglycaemia), a common problem that affects up to 15% of otherwise healthy babies, and a preventable cause of brain damage, according to new research published in The Lancet.

27 Sep 2013

Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

The National Institutes of Health awarded Joslin Diabetes Center $24.3 million to fund a clinical trial to study a potential treatment for kidney disease in people with type 1 diabetes.

27 Sep 2013

Center of Reproductive Medicine announces participation in Thrive-IVF Research Study

The Center of Reproductive Medicine today announced its participation in the Thrive-IVF Research Study, a Phase 2 clinical trial sponsored by Nora Therapeutics, Inc., to evaluate the efficacy, safety and tolerability of NT100 in women who have had repeated in vitro fertilization (IVF) failures despite having good quality embryos.

26 Sep 2013

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced the initiation of a global clinical program to evaluate its drug candidate LUM001 in children with Alagille syndrome. The first patient has been dosed in the IMAGO Phase II study being conducted in the U.K., and enrollment of pediatric patients is expected to begin later this year in the ITCH Phase II study in the U.S.

26 Sep 2013

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

NovaRx Corporation announced that the detailed results from the randomized Phase III trial of Lucanix (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer will be presented at the European Society for Medical Oncology 2013 annual meeting in Amsterdam.

26 Sep 2013

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Abiraterone acetate, a recently FDA-approved drug used to treat men with metastatic castration-resistant prostate cancer, significantly delays progression of pain and quality of life deterioration when taken in conjunction with prednisone.

25 Sep 2013

Sulfasalazine drug does not reduce diarrhea for patients receiving pelvic radiation therapy: Study

Sulfasalazine, a drug commonly prescribed to reduce diarrhea in patients with inflammatory bowel disease, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area a Mayo Clinic-led study has found.

24 Sep 2013

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

Boehringer Ingelheim and Eli Lilly and Company today announced results from two post-hoc, pooled analyses of data from placebo-controlled clinical trials, which examined the safety of the dipeptidyl peptidase-4 inhibitor linagliptin in adults with type 2 diabetes.

24 Sep 2013

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

BioLineRx, a biopharmaceutical development company, announced today that it has filed the necessary regulatory submissions to commence a Phase 1/2 trial for BL-7010 - for the treatment of celiac disease - with the Finnish National Supervisory Authority for Welfare and Health (Valvira). The relevant ethics committee has already approved commencement of the study.

24 Sep 2013

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

A drug formerly used to treat the skin disorder psoriasis has shown encouraging results in a phase 2 trial to assess its effectiveness in treating type 1 diabetes, according to new research published in The Lancet Diabetes & Endocrinology.

24 Sep 2013

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

Novartis announced today that the European Commission approved once-daily Ultibro® Breezhaler® (indacaterol 85 mcg / glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labour and Welfare (MHLW) approved once-daily Ultibro® Inhalation Capsules (glycopyrronium 50 mcg / indacaterol 110 mcg), delivered through the Breezhaler® device, for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro® Breezhaler® / Ultibro® Inhalation Capsules were developed under the name QVA149.

23 Sep 2013

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in combination with methotrexate for the treatment of adult patients (18 years or older) with active psoriatic arthritis.

23 Sep 2013

Researchers report encouraging results from T1DAL study on type 1 diabetes

Encouraging results from the T1DAL study (Targeting effector memory T cells with alefacept in new onset type 1 diabetes), led by Mark R. Rigby MD, PhD from Indiana University and Riley Hospital for Children in Indianapolis and sponsored by the Immune Tolerance Network (ITN) with additional support from JDRF, are published today in The Lancet Diabetes & Endocrinology.

23 Sep 2013

Mother who smoke during her pregnancy may transmit asthma to future generation

Asthma is a serious public health problem. An estimated 300 million people worldwide suffer from this sometimes deadly lung disease, a number expected to increase to 400 million by 2025. One well-established risk factor for asthma is having a mother who smoked during her pregnancy.

21 Sep 2013

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

Bayer HealthCare announced today that the the European Committee for Medicinal Products for Human Use recommended Xofigo (radium Ra 223 dichloride) for approval with a proposed indication for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.

20 Sep 2013

An in-depth approach to examine placebo effect and its impact on doctor-patient relationship

The findings of a comprehensive review of the placebo phenomenon and its consequences for clinical medicine are contained in a new article, "Placebo and the New Physiology of the Doctor-Patient Relationship," (http://bit.ly/14QfSur) published in Physiological Reviews.

20 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

19 Sep 2013

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

Isis Pharmaceuticals, Inc. announced today that follow-up preliminary data from a single dose, open-label Phase 1 study of ISIS-SMNRx in children with spinal muscular atrophy, show that most SMA children receiving the two highest doses of the drug (6 mg and 9 mg) continued to show improvements in muscle function tests up to 14 months after a single injection of the drug.

19 Sep 2013

New evidence suggests that taking vitamin B supplements may help reduce risk of stroke

New evidence suggests that taking vitamin B supplements may help reduce the risk of stroke. The research appears in the September 18, 2013, online issue of Neurology®, the medical journal of the American Academy of Neurology.

19 Sep 2013

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

...

18 Sep 2013

Placebo News and Research

Dextrose gel could treat neonatal hypoglycemia

Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

Center of Reproductive Medicine announces participation in Thrive-IVF Research Study

Lumena Pharmaceuticals initiates LUM001 clinical program in children with ALGS

Results of NovaRx's Lucanix Phase III trial in non-small cell lung cancer to be presented at ESMO 2013

Drug to treat metastatic castration-resistant prostate cancer delays progression of pain and quality of life deterioration in men

Sulfasalazine drug does not reduce diarrhea for patients receiving pelvic radiation therapy: Study

Boehringer Ingelheim, Lilly present post-hoc analysis data from linagliptin clinical trials at EASD 2013

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

Alefacept drug shows encouraging results in phase 2 trial for type 1 diabetes

European Commission and Japan approve once-daily dual bronchodilator Ultibro Breezhaler (QVA149) nearly simultaneously, for COPD patients

FDA approves STELARA (Ustekinumab) for treatment of active psoriatic arthritis

Researchers report encouraging results from T1DAL study on type 1 diabetes

Mother who smoke during her pregnancy may transmit asthma to future generation

CHMP recommends approval of Xofigo for CRPC, symptomatic bone and visceral metastases

An in-depth approach to examine placebo effect and its impact on doctor-patient relationship

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Isis Pharmaceuticals announces preliminary data from ISIS-SMNRx Phase 1 study in infants with SMA

New evidence suggests that taking vitamin B supplements may help reduce risk of stroke

GSK Returns Vercirnon Rights To Chemocentryx After Phase III Flop

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News